Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Cortexyme, Inc. Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 July 27, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 July 27, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections June 21, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Appoints June Bray to its Board of Directors June 13, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Appoints Dr. Philip Low to Its Board of Directors May 20, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Successfully Completes Acquisition of Novosteo May 20, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases May 12, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Announces Agreement to Acquire Novosteo May 10, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population March 21, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors March 15, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Present New GAIN Trial Data at AD/PD 2022 March 14, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones February 01, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Announces Change in Executive Leadership Team February 01, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application January 26, 2022 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th November 23, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021 November 11, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th November 04, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression October 26, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021 September 27, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588 September 08, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th September 07, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit August 25, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit August 18, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Provides Business Update and Reports Second Quarter 2021 Results August 09, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th August 04, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021 July 26, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection July 23, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Present New Data at AAIC 2021 July 22, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 July 21, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Cortexyme to Host Symposium at AAIC 2021 July 19, 2021 From Cortexyme, Inc. Via Business Wire Tickers CRTX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
